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ancer is a deadly disease affecting and
killing many people every year. For 2019,
the estimated number of new cancer cases
exceeds 1.5 million, and the estimated number
of deaths caused by cancer exceeds six-hundred
thousand.1 Treatments for cancer certainly exist;
although current treatments are often costly and are
not always effective in the long-run. The treatments
also come with side effects often associated with
the destruction of healthy, noncancerous cells.
The expansion of alternatives for treating cancer
is a constant objective for the medical community,
and researchers are experimenting with many new
solutions in order to provide new opportunities to treat
cancer. One potential treatment in development is
snake venom, a substance that is normally poisonous
to humans in its unmodified form.
Although snake venom as a whole can be
harmful to humans, it is composed of many different
proteins, enzymes, and carbohydrates. If the different
molecules constituting the venom are extracted and
isolated, the individual molecules can provide benefits
for humans without the harmful effects of the entire
venom. For example, the drug captopril is derived
from snake venom and treats high blood pressure and
heart failure. As long as the entire venom is not used,
the separate components can elicit healthy effects in
humans. In the 1940s, researchers began isolating
enzymes and non-enzyme proteins from snake venom
and experimented with the proteins for effects on
tumor cells. Clinical testing with the venom became
more prevalent from the 1960s onward.2, 3
The proteins in snake venom harbor a variety
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of cancerfighting characteristics.
One such type of protein is the disintegrin.
Disintegrins are non-enzymatic proteins found
in snake venom and inhibit angiogenesis, the
development of new blood vessels. Angiogenesis
allows tumor cells to invade nearby healthy tissue and
metastasize. Treatment with disintegrins has been
shown to suppress the spread of tumors due to the
antiangiogensis activity of disintegrins.3
L-amino acid oxidases (LAAOs) are enzymatic
proteins found in snake venom and demonstrate
anti-tumor effects. LAAO converts L-amino acid to
alpha-keto acid and releases the byproducts ammonia
and hydrogen peroxide. Hydrogen peroxide is a major
proposed mechanism of LAAO-induced toxicity, as it
can act as reactive oxygen species (ROS) that can
diffuse into cancer cells and cause cell death. Studies
have shown that the effects of ROS are more likely to
harm cancer cells than normal cells, possibly due to
the higher metabolic activity present in cancer cells.
The higher metabolic activity leads to higher levels
of ROS in cancer cells; hence, the cancer cells are
more susceptible to further increases in ROS levels
than normal cells. The evidence of selectivity of LAAO
activity towards cancer cells is beneficial for cancer
therapy, as the enzyme does not seem to have a high
potential to harm healthy cells.4
Metalloproteases (MPs) are another group of enzymes
derived from the venom and can also exhibit antitumor activity.5 One type of MP, known as jarahagin
(produced by the species Bothrops jararaca), has
demonstrated cytotoxic effects on melanoma cells,
as well as inhibition of cancer cell adhesion.6 Cell
adhesion contributes to tumor spread; thus, by
inhibiting adhesion, jarahagin can prevent metastasis,
which is the spread of cancer to a secondary site.
Phospholipase A2 (PLA2) is another enzyme

belonging
to snake
venom and has
demonstrated cytotoxic and
antiangiogenesis effects.5
Lectins (proteins that bind to sugars) belonging
to snake venom have been shown to inhibit the
growth of certain types of cancer cells, such as renal
and pancreatic cancer cells.5 The proteins have
also demonstrated cytotoxic activity. In a particular
experiment, the lectin B1L, belonging to Bothrops
leucurus venom, was tested and induced apoptosis on
a variety of cancer cells, including myeloid leukemia
cells, lung carcinoma, and larynx carcinoma cells.
Furthermore, healthy cells were not harmed by the
protein.7 Thus, snake venom lectins can be especially
helpful in treating certain types of cancer.
The process of collecting the venom and
determining its effects on cancer takes multiple
steps. The species of snake from which the venom
is collected depends on the proteins of interest, as
the type of venom varies among species. It may be
easier to collect venom in the summer as opposed
to the winter, as the venom is more liquefied in the
summer.8 Once the species is identified and captured,
the snake must be kept in conditions suitable for living.
A snake can die when kept in conditions unlike its
natural habitat, and high occurrences of snake deaths
could shift a vulnerable species closer to becoming
endangered.2 Once the venom is collected, the
proteins must be isolated using various purification
techniques, such as size-exclusion, ion exchange, and
affinity chromatography. Edman sequencing can be
used to determine the sequences of small proteins, if
necessary.9 Once the individual proteins of the venom
are identified and isolated, researchers can test the
effects of the proteins on cancer cell activity.
The isolation and utilization of snake venom
components is a valuable cancer-fighting technique
but is not without its flaws. The immune system can
possibly react to foreign proteins injected into the
bloodstream. Immunosuppression may help prevent
rejection of the proteins by the immune system, but
would also render the body vulnerable to infectious
agents. Encapsulation of the proteins in nanocarriers
for slow, controlled release of the proteins may help
prevent adverse reactions by the immune system.

The technique of encapsulation, however, has not
fully been mastered and is currently in development.3,
10
Furthermore, the mechanisms of action of many
cancer-fighting proteins have not yet been confirmed,
which is why many of these proteins are not yet
available for purchase from pharmacies.11 Until the
exact behavior of the snake venom components
are made certain, there is no guarantee that these
proteins cannot destroy healthy, noncancerous cells.
Although many of the proteins have demonstrated
selectivity towards tumor cells in experiments, further
research should be done to confirm the abilities of
these molecules to discriminate between cancerous
and healthy cells and to determine potential methods
to circumvent any possibility of the proteins harming
healthy cells.
Snake venom as a treatment for cancer is
promising and could be an effective alternative to
current treatments. Whether or not the use of snake
venoms would be more cost effective or less painful
than current treatments has not yet been confirmed,
as the treatment is not a common practice. Further
research on the behavior of these proteins and on
potential costs of treating cancer patients with the
venom should provide more insight about the value of
the treatment. In the future, when more information is
made available, snake venom could potentially serve
as an incredibly valuable alternative to current cancer
treatments.
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